# Zebra Medical Vision

> AI\-powered medical imaging analytics for population\-scale risk detection and preventive care pathways

## At a glance

| Field | Value |
| --- | --- |
| Category | Data & Analytics |
| Type | Solutions Provider |
| Region | EMEA |
| Headquarters | Shefayim, Israel |
| Founded | 2014 |
| Stage | Growth |
| Employees | 51-200 |
| Funding | Acquired by Nanox (NASDAQ: NNOX) in 2021 for up to USD 200M; USD 53M raised pre-acquisition |

## Overview

Zebra Medical Vision is an AI medical imaging analytics platform founded in 2014 and headquartered in Shefayim, Israel. The company serves health systems, academic medical centers, and healthcare providers by applying deep learning to routine radiology data to detect chronic and acute conditions that would otherwise go unnoticed. Its technology supports population health management and enables risk stratification at scale, with applications in health insurance underwriting and preventive care program design.

The platform analyzes CT scans, chest X-rays, and mammograms using FDA-cleared algorithms, delivering structured clinical findings through a SaaS model priced at approximately USD 1 per study. The AI1 (All-in-One) platform bundles multiple disease-detection algorithms into a single workflow integration, covering conditions including coronary artery disease, osteoporosis, liver disease, and breast cancer. As of 2020, the company had received more FDA clearances than any other AI medical imaging startup.

In August 2021, Zebra Medical Vision was acquired by Nanox (NASDAQ: NNOX) for up to USD 200M and now operates as Nanox.AI, a division of Nano-X Imaging Ltd. Before the acquisition, the company served over 1,100 hospitals and care providers globally and had raised USD 53M from investors including Khosla Ventures, Nvidia, and aMoon Ventures.

## Products & services

### AI1 \(All\-in\-One\) Platform

A SaaS-based medical imaging analytics platform that applies all applicable FDA-cleared algorithms to a submitted radiology study, delivering structured AI findings in a single workflow. Priced at approximately USD 1 per study.

**Key features:**

- Multi\-condition detection from a single imaging study
- Integration with existing PACS, EMR, and radiology reporting systems
- Supports CT, mammography, and chest X\-ray modalities

*Target users:* Radiologists, hospital imaging departments, health systems

### HealthCCSng \-\- Cardiac AI Solution

FDA 510(k)-cleared and CE-marked algorithm that detects coronary artery calcification on non-gated CT scans, identifying patients at elevated risk for coronary artery disease.

**Key features:**

- Incidental finding detection on existing non\-gated CT data
- Structured output for clinical decision support
- Validated in large\-scale health system deployments

*Target users:* Health systems, preventive cardiology programs

### HealthOST \-\- Bone AI Solution

FDA-cleared and CE-marked algorithm that detects vertebral compression fractures and measures bone mineral density from chest and abdominal CT scans to support osteoporosis diagnosis.

**Key features:**

- Only FDA/CE\-cleared population\-scale solution for vertebral fracture detection
- CPT code 0691T established for this algorithm category
- ADOPT study demonstrates improved detection rates vs\. NHS averages

*Target users:* Health systems, osteoporosis screening programs

### HealthFLD \-\- Liver AI Solution

FDA 510(k)-cleared algorithm that measures liver density in contrast and non-contrast CT scans to detect metabolic dysfunction-associated fatty liver disease (MASLD/NAFLD).

**Key features:**

- Quantitative liver density measurement
- Works on both contrast and non\-contrast CT
- Supports early MASLD/NAFLD detection

*Target users:* Gastroenterology programs, population health teams

### HealthMammo \-\- Mammography AI Solution

FDA-cleared mammography screening algorithm achieving 92% accuracy in breast cancer detection, compared to 87% for radiologists alone. Trained on 350,000 mammograms with confirmed diagnoses.

**Key features:**

- 92% detection accuracy vs\. 87% baseline
- Trained on large labeled mammography dataset
- Designed as a second\-reader tool

*Target users:* Radiology departments, breast cancer screening programs

### Chest X\-Ray Reader

Automated AI analysis of chest X-rays for detecting pleural effusions, pneumothorax, and other acute findings.

**Key features:**

- Automated acute finding detection
- Designed for high\-volume reading environments

*Target users:* Emergency medicine, radiology departments

## Category & focus

- Subcategories: Medical imaging AI, Population health analytics, Risk stratification
- Insurance verticals: Health
- Target customers: Carriers, Employers

## Notable customers

- Intermountain Healthcare \(strategic investor and customer\)
- Corewell Health
- Atlantic Health System
- Cedars\-Sinai Medical Center
- University of Oxford
- Telerad Tech network \(150\+ hospitals across 20 developing countries\)

## Links

- Website: <https://www.nanox.vision/ai/>
- Directory profile: <https://insurtechlist.com/companies/zebra-medical-vision/>
- Parent company: <https://www.nanox.vision/>
- Investor relations: <https://investors.nanox.vision/>
- Acquisition announcement: <https://www.businesswire.com/news/home/20210810005663/en/In-an-up-to-200M-Acquisition-by-Nanox-Zebra-Medical-Vision-Brings-Its-AI-to-Reimagine-Radiology-Globally>

---

*Last updated: 2026\-05\-18*